{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:22:13Z","timestamp":1789024933415,"version":"build-2803163510"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T00:00:00Z","timestamp":1329177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T00:00:00Z","timestamp":1329177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/pcan.2012.1","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T16:45:28Z","timestamp":1329237928000},"page":"222-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Role of 5\u03b1-reductase inhibitors in benign prostatic diseases"],"prefix":"10.1038","volume":"15","author":[{"given":"F","family":"Azzouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,14]]},"reference":[{"key":"BFpcan20121_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0303-7207(02)00368-4","volume":"198","author":"J Imperato-McGinley","year":"2002","unstructured":"Imperato-McGinley J, Zhu Y . Androgens and male physiology \u2013 The syndrome of 5\u03b1-reductase-2 deficiency. Mol Cell Endocrinol 2002; 198: 51\u201359.","journal-title":"Mol Cell Endocrinol"},{"key":"BFpcan20121_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1210\/jcem-38-1-113","volume":"38","author":"P Siiteri","year":"1974","unstructured":"Siiteri P, Wilson J . Testosterone formationand metabolism during male sexual differentiationin the human embryo. J Clin Endocrinol Metab 1974; 38: 113\u2013125.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan20121_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev.bi.63.070194.000325","volume":"63","author":"DW Russell","year":"1994","unstructured":"Russell DW, Wilson JD . Steroid 5a-reductase: two genes\/two enzymes. Ann Rev Biochem 1994; 63: 25\u201361.","journal-title":"Ann Rev Biochem"},{"key":"BFpcan20121_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cell.2010.06.001","volume":"142","author":"V Cantagril","year":"2010","unstructured":"Cantagril V, Lefeber D, Ng B, Guan Z, Silhavy J, Bielas S et al. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 2010; 142: 203\u2013217.","journal-title":"Cell"},{"key":"BFpcan20121_CR5","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1210\/endo-114-6-2100","volume":"114","author":"T Saartok","year":"1984","unstructured":"Saartok T, Dahlberg E, Gustafsson JA . Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology 1984; 114: 2100\u20132106.","journal-title":"Endocrinology"},{"key":"BFpcan20121_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/BF03343844","volume":"24","author":"A Ciloti","year":"2001","unstructured":"Ciloti A, Danza D, Serio M . Clinical applications of 5\u03b1-reductase inhibitors. J Endocrinol Invest 2001; 24: 199\u2013203.","journal-title":"J Endocrinol Invest"},{"key":"BFpcan20121_CR7","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1126\/science.186.4170.1213","volume":"186","author":"J Imperato-McGinley","year":"1974","unstructured":"Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE . Steroid 5\u03b1-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213\u20131215.","journal-title":"Science"},{"key":"BFpcan20121_CR8","first-page":"1","volume":"25","author":"Y Zhu","year":"2005","unstructured":"Zhu Y, Sun G . 5\u03b1-reductase isozymes in the prostate. J Med Sci 2005; 25: 1\u201312.","journal-title":"J Med Sci"},{"key":"BFpcan20121_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.steroids.2009.10.005","volume":"75","author":"S Aggarwal","year":"2010","unstructured":"Aggarwal S, Thareja S, Verma A, Bhardwaj T, Kumar M . An overview on 5\u03b1 reductase inhibitors. Steroids 2010; 75: 109\u2013153.","journal-title":"Steroids"},{"key":"BFpcan20121_CR10","first-page":"550","volume":"41","author":"L Drake","year":"1999","unstructured":"Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC . The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 1999; 41: 550\u2013554.","journal-title":"J Am Acad Dermatol"},{"key":"BFpcan20121_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0022-5347(01)62141-4","volume":"161","author":"PN Span","year":"1999","unstructured":"Span PN, Voller MC, Smals AG, Sweep F, Schalken J, Fenely M et al. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 1999; 161: 332\u2013337.","journal-title":"J Urol"},{"key":"BFpcan20121_CR12","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1210\/jc.2003-030330","volume":"89","author":"RV Clark","year":"2004","unstructured":"Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S . Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179\u20132184.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan20121_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/01.ju.0000136430.37245.b9","volume":"172","author":"G Andriole","year":"2004","unstructured":"Andriole G, Humphrey P, Ray P, Gleave M, Trachtenburg J, Thomas L et al. Effect of the dual 5\u03b1-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004; 172: 915\u2013919.","journal-title":"J Urol"},{"key":"BFpcan20121_CR14","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1002\/pros.20499","volume":"66","author":"M Gleave","year":"2006","unstructured":"Gleave M, Qian J, Andreou M, Pommerville P, Chin J, Casey R et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer-Results from a 4 month pre-radical prostatectomy study. Prostate 2006; 66: 1674\u20131685.","journal-title":"Prostate"},{"key":"BFpcan20121_CR15","first-page":"293","volume":"2","author":"K Yamana","year":"2010","unstructured":"Yamana K, Labrie F, Luu-The V . Human type 3 5\u03b1-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited finasteride and dutasteride. Horm Mol Biol Clin Invest 2010; 2: 293\u2013299.","journal-title":"Horm Mol Biol Clin Invest"},{"key":"BFpcan20121_CR16","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","volume":"327","author":"G Gormley","year":"1992","unstructured":"Gormley G, Stoner E, Bruskewitz R, Imperato-McGinely J, Walsh P, McConnell J et al. The effect of finasteride in men with benign prostatic hyperplasia. NEJM 1992; 327: 1185\u20131191.","journal-title":"NEJM"},{"key":"BFpcan20121_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0022-5347(01)66524-8","volume":"155","author":"HA Guess","year":"1996","unstructured":"Guess HA, Gormley GJ, Stoner E, Oesterling JE . The effect of finasteride on prostate specific antigen: review of available data. J Urol 1996; 155: 3.","journal-title":"J Urol"},{"key":"BFpcan20121_CR18","first-page":"1993","volume":"627","author":"HA Guess","year":"1920","unstructured":"Guess HA, Heyse JF, Gormley GJ, Stoner E, Oesterling JE . Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. Urol Clin North Am 20; 627: 1993.","journal-title":"Urol Clin North Am"},{"key":"BFpcan20121_CR19","first-page":"1998","volume":"195","author":"GL Andriole","year":"1952","unstructured":"Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 52; 195: 1998.","journal-title":"Urology"},{"key":"BFpcan20121_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","volume":"60","author":"C Roehrborn","year":"2002","unstructured":"Roehrborn C, Boyle P, Nickel J, Hoefner K, Andriole G . Efficacy and safety of a dual inhibitor of 5alpha-reductase types 1 and 2 (dutasteride) in men with benign prostate hyperplasia. Urology 2002; 60: 434\u2013441.","journal-title":"Urology"},{"key":"BFpcan20121_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1056\/NEJM199802263380901","volume":"338","author":"J McConnell","year":"1998","unstructured":"McConnell J, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe L et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostate hyperplasia. N Eng J Med 1998; 338: 557\u2013563.","journal-title":"N Eng J Med"},{"key":"BFpcan20121_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1464-410X.2011.10195.x","volume":"108","author":"J Nickel","year":"2011","unstructured":"Nickel J, Gilling P, Tammela T, Morril B, Wilson T, Rittmaster R . Comparison of dutasteride and finasteride for treating benign prostate hyperplasia: the enlarged prostate international comparator study (EPICS). BJU Int 2011; 108: 388\u2013394.","journal-title":"BJU Int"},{"key":"BFpcan20121_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"I Thompson","year":"2003","unstructured":"Thompson I, Goodman P, Tangen C, Lucia MS, Miller GJ, Ford LG et al. The influence of finasteride on the development of prostate cancer. N Eng J Med 2003; 349: 215\u2013224.","journal-title":"N Eng J Med"},{"key":"BFpcan20121_CR24","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"G Andriole","year":"2010","unstructured":"Andriole G, Bostwick D, Brawley O, Gomella OW, Marberger M, Montorsi F et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192\u20131202.","journal-title":"N Engl J Med"},{"key":"BFpcan20121_CR25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.juro.2006.04.024","volume":"176","author":"L Marks","year":"2006","unstructured":"Marks L, Andriole G, Fitzpatrick J, Schulman C, Roehrborn C . The interpretation of serum prostate specific antigen in men receiving 5\u03b1-reductase inhibitors: a review and clinical recommendations. J Urol 2006; 176: 868\u2013874.","journal-title":"J Urol"},{"key":"BFpcan20121_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<234::AID-PROS3>3.0.CO;2-4","volume":"39","author":"M Brawer","year":"1999","unstructured":"Brawer M, Lin D, Wiliford W, Jones K, Lepor H . The effect of finasteride and\/or terazosin on serum PSA: results of VA cooperative study #359. Prostate 1999; 39: 234\u2013239.","journal-title":"Prostate"},{"issue":"Suppl 5","key":"BFpcan20121_CR27","first-page":"s141","volume":"12","author":"J Nickel","year":"2006","unstructured":"Nickel J . BPH: costs and treatment outcomes. Am J Manag Care 2006; 12 (Suppl 5): s141\u2013s148.","journal-title":"Am J Manag Care"},{"key":"BFpcan20121_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/00019053-200624020-00006","volume":"24","author":"R DiSantostefano","year":"2006","unstructured":"DiSantostefano R, Biddle A, Lavelle J . The long-term effectiveness of treatments for benign prostatic hyperplasia. Pharmacoeconomics 2006; 24: 171\u2013191.","journal-title":"Pharmacoeconomics"},{"key":"BFpcan20121_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/sj.pcan.4500841","volume":"9","author":"C Roehrborn","year":"2006","unstructured":"Roehrborn C, Marks L, Harkaway R . Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis 2006; 9: 30\u201334.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan20121_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0960-0760(99)00030-8","volume":"68","author":"C Lehle","year":"1999","unstructured":"Lehle C, Radvanyi F, Gil Diez de Medina S, Ouafik L, Gerard H, Chopin D et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 1999; 68: 189\u2013195.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFpcan20121_CR31","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1677\/joe.0.1560509","volume":"156)","author":"F Habib","year":"1998","unstructured":"Habib F, Ross M, Bayne C, Grigor K, Buck A, Bollina P et al. The localization and expression of 5\u03b1-reductase types 1 and 2 mRNAs in human hyperplastic prostate and in prostate primary cultures. J Endocrin 1998; 156): 509\u2013517.","journal-title":"J Endocrin"},{"key":"BFpcan20121_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0022-5347(01)66461-9","volume":"155","author":"SJ Jacobsen","year":"1996","unstructured":"Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling J, Lieber M . Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595\u2013600.","journal-title":"J Urol"},{"key":"BFpcan20121_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0022-5347(05)67984-0","volume":"163","author":"RO Roberts","year":"2000","unstructured":"Roberts RO, Jacobsen SJ, Jacobsen D, Rhodes T, Girman C, Lieber M . Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000; 163: 107\u2013113.","journal-title":"J Urol"},{"issue":"Suppl 2","key":"BFpcan20121_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1464-410X.2006.06097.x","volume":"97","author":"JM Fitzpatrick","year":"2006","unstructured":"Fitzpatrick JM . The natural history of benign prostatic hyperplasia. BJU Int 2006; 97 (Suppl 2): 3\u20136.","journal-title":"BJU Int"},{"key":"BFpcan20121_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0022-5347(01)64508-7","volume":"158","author":"SJ Jacobsen","year":"1997","unstructured":"Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481\u2013487.","journal-title":"J Urol"},{"key":"BFpcan20121_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0022-5347(01)62081-0","volume":"161","author":"C Kolman","year":"1999","unstructured":"Kolman C, Girman CJ, Jacobsen SJ, Lieber M . Distribution of post-void residual urine in randomly selected men. J Urol 1999; 161: 122\u2013127.","journal-title":"J Urol"},{"issue":"Suppl 2","key":"BFpcan20121_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1464-410X.2006.06098.x","volume":"97","author":"C Roehrborn","year":"2006","unstructured":"Roehrborn C . Definition of at risk patients: baseline variables. BJU Int 2006; 97 (Suppl 2): 7\u201311.","journal-title":"BJU Int"},{"key":"BFpcan20121_CR38","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM, Andriole G, Dixon C, Kusek J et al. The Medical Therapy of Prostatic Symptoms (MTOPS) Research Group.The long-term effect of doxazosin,finasteride, and combination therapy on the clinical progression of benignprostatic hyperplasia. N Engl J Med 2003; 349: 2387\u20132398.","journal-title":"N Engl J Med"},{"key":"BFpcan20121_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0022-5347(17)40731-2","volume":"141","author":"W Mebust","year":"1989","unstructured":"Mebust W, Holtgrewe H, Cockett A, Peters P . Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluation of 3,885 patients. J Urol 1989; 141: 243.","journal-title":"J Urol"},{"key":"BFpcan20121_CR40","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1464-410X.2006.06110.x","volume":"97","author":"Roehrborn CG for the ALTESS Study Group","year":"2006","unstructured":"Roehrborn CG for the ALTESS Study Group. Alfuzosin 10\u2009mg once daily prevents BPH overall clinical progression but not acute urinary retention occurrence: results of a 2-year placebo controlled study. BJU Int 2006; 97: 734\u2013741.","journal-title":"BJU Int"},{"key":"BFpcan20121_CR41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"C Roehrborn","year":"2010","unstructured":"Roehrborn C, Siami P, Barkin J, Damiao R, major-Walker K, Nandy I et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123\u2013131.","journal-title":"Eur Urol"},{"key":"BFpcan20121_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","volume":"61","author":"R Kirby","year":"2003","unstructured":"Kirby R, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary M et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in symptomatic benign prostate hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology 2003; 61: 119\u2013126.","journal-title":"Urology"},{"key":"BFpcan20121_CR43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJM199608223350801","volume":"335","author":"H Lepor","year":"1996","unstructured":"Lepor H, Williford WO, Barry MJ, Brawer M, Dixon C, Gormley G et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533\u2013539.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"BFpcan20121_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1464-410X.2003.04636.x","volume":"93","author":"C Roehrborn","year":"2004","unstructured":"Roehrborn C . The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int 2004; 93 (Suppl 1): 21\u201326.","journal-title":"BJU Int"},{"key":"BFpcan20121_CR45","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","volume":"44","author":"J Barkin","year":"2003","unstructured":"Barkin J, Guimaraes M, Jacobi G, Taylor S, Van Vierssen Trip O . Alpha blocker monotherapy can be withdrawn in the majority of men following initial combination therapy with dual 5\u03b1-reductase inhibitor dutasteride. Eur Urol 2003; 44: 461\u2013466.","journal-title":"Eur Urol"},{"key":"BFpcan20121_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1046\/j.1464-410x.2000.00322.x","volume":"85","author":"SJ Foley","year":"2000","unstructured":"Foley SJ, Bailey DM . Microvessel density in prostatic hyperplasia. BJU Int 2000; 85: 70\u201377.","journal-title":"BJU Int"},{"key":"BFpcan20121_CR47","first-page":"498","volume":"163","author":"A Kirschenbaum","year":"2001","unstructured":"Kirschenbaum A . Editorial comment. J Urol 2001; 163: 498.","journal-title":"J Urol"},{"key":"BFpcan20121_CR48","first-page":"151","volume":"73","author":"ST Hasan","year":"1994","unstructured":"Hasan ST, German K, Derry CD . Same day diagnostic service for new cases of hematuria\u2014a district general hospital experience. Br J Urol 1994; 73: 151\u2013153.","journal-title":"Br J Urol"},{"key":"BFpcan20121_CR49","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/S0022-5347(17)36446-7","volume":"149","author":"S Marshall","year":"1993","unstructured":"Marshall S, Narayan P . Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation. J Urol 1993; 149: 1553\u20131554.","journal-title":"J Urol"},{"key":"BFpcan20121_CR50","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1210\/endo.139.11.6303","volume":"139","author":"AC Levine","year":"1998","unstructured":"Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA et al. Androgens induce the expression of vascular endothelial growth factors in human fetal prostatic fibroblasts. Endocrinology 1998; 139: 4672.","journal-title":"Endocrinology"},{"key":"BFpcan20121_CR51","first-page":"1936","volume":"116","author":"Z Du","year":"2003","unstructured":"Du Z, Fujiyama C, Chen Y, Masaki Z . Expression of hypoxia- inducible factor 1\u03b1 in human normal, benign, and malignant prostate tissue. Chin Med J 2003; 116: 1936\u20131939.","journal-title":"Chin Med J"},{"key":"BFpcan20121_CR52","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.urology.2006.03.038","volume":"68","author":"AG Lekas","year":"2006","unstructured":"Lekas AG, Lazaris AC, Chrisofos M, Papatsoris AG, Lappas D, Patsouris E et al. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. Urology 2006; 68: 436\u2013441.","journal-title":"Urology"},{"key":"BFpcan20121_CR53","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3109\/00365590903337896","volume":"43","author":"JH Ku","year":"2009","unstructured":"Ku JH, Shin JK, Cho MC, Myung JK, Moon KC, Paick JS . Effect of dutasteride on the expression of hypoxia inducible factor 1\u03b1, vascular endothelial growth factor and microvessel density in rat and human prostate tissue. Scand J Urol Nephrol 2009; 43: 445\u2013453.","journal-title":"Scand J Urol Nephrol"},{"key":"BFpcan20121_CR54","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/(SICI)1097-0045(19990701)40:2<83::AID-PROS3>3.0.CO;2-N","volume":"40","author":"C Saez","year":"1999","unstructured":"Saez C, Gonzalez-Baena AC, Japon MA, Giraldez J, Segura DI, Rodriguez-Vallejo JM et al. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate 1999; 40: 83.","journal-title":"Prostate"},{"issue":"Suppl","key":"BFpcan20121_CR55","first-page":"332","volume":"159","author":"S-Y Moon","year":"1998","unstructured":"Moon S-Y, Moon W-C, Choi HR, Gi Y-J . Finasteride inhibits angiogenesis and expression of VEGF in human BPH. J Urol 1998; 159 (Suppl): 332, abstract 1276.","journal-title":"J Urol"},{"key":"BFpcan20121_CR56","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/j.1464-410X.2005.05849.x","volume":"96","author":"JF Donohue","year":"2005","unstructured":"Donohue JF, Hayne D, Karnik U, Thomas DR, Foster MC . Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int 2005; 96: 1319\u20131322.","journal-title":"BJU Int"},{"key":"BFpcan20121_CR57","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0022-5347(05)65188-9","volume":"167","author":"DA Hochberg","year":"2002","unstructured":"Hochberg DA, Basillote JB, Armenakas NA, Vasovic L, Shevchuk M, Pareek G et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 2002; 167: 1731\u20131733.","journal-title":"J Urol"},{"issue":"Suppl","key":"BFpcan20121_CR58","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/00005392-199904020-00455","volume":"161","author":"DM Bailey","year":"1999","unstructured":"Bailey DM, Foley SJ, Wedderburn A . Effect of Finasteride on microvessel density (MVD) in patients with recurrent haematuria related to prostatic hypertrophy (BPH). J Urol 1999; 161 (Suppl): 363, abstract 1406.","journal-title":"J Urol"},{"key":"BFpcan20121_CR59","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1046\/j.1464-410x.2000.00671.x","volume":"85","author":"E Lekas","year":"2000","unstructured":"Lekas E, Bergh A, Damber JE . Effects of finasteride and bicalutamide on prostatic blood flow in the rat. BJU Int 2000; 85: 962.","journal-title":"BJU Int"},{"key":"BFpcan20121_CR60","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.urology.2008.08.461","volume":"73","author":"S Kravchick","year":"2009","unstructured":"Kravchick S, Cytron S, Mamonov A, Peled R, Linov L . Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. Urology 2009; 73: 1274\u20131278.","journal-title":"Urology"},{"key":"BFpcan20121_CR61","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0022-5347(01)66782-X","volume":"154","author":"P Puchner","year":"1995","unstructured":"Puchner P, Miller M . The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995; 154: 1779.","journal-title":"J Urol"},{"key":"BFpcan20121_CR62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0090-4295(97)00614-6","volume":"51","author":"M Miller","year":"1998","unstructured":"Miller M, Puchner P . Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 1998; 51: 237\u2013242.","journal-title":"Urology"},{"key":"BFpcan20121_CR63","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/(SICI)1097-0045(19970515)31:3<180::AID-PROS6>3.0.CO;2-P","volume":"31","author":"B Carlin","year":"1997","unstructured":"Carlin B, Bodner D, Spirnak J, Resnick M . Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate 1997; 31: 180.","journal-title":"Prostate"},{"key":"BFpcan20121_CR64","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S0022-5347(05)67910-4","volume":"163","author":"S Foley","year":"2000","unstructured":"Foley S, Soloman L, Wedderburn A, Kashif K, Summerton D, Basketter V et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 2000; 163: 496\u2013401.","journal-title":"J Urol"},{"key":"BFpcan20121_CR65","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0022-5347(05)65011-2","volume":"167","author":"MC Kearney","year":"2002","unstructured":"Kearney MC, Bingham JB, Bergland R, Meade-D\u2019Alisera P, Puchner PJ . Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 2002; 167: 2489\u20132491.","journal-title":"J Urol"},{"key":"BFpcan20121_CR66","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1464-410X.2006.06619.x","volume":"99","author":"RG Hahn","year":"2007","unstructured":"Hahn RG, Fagerstrom T, Tammela TL, Van Vierssen Trip O, Beisland HP, Duggan A et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int 2007; 99: 587\u2013594.","journal-title":"BJU Int"},{"key":"BFpcan20121_CR67","first-page":"1085","volume":"15","author":"L Boccon-Gibod","year":"2005","unstructured":"Boccon-Gibod L, Valton M, Ibrahim H, Boccon-Gibod L, Comenducci A . Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate. Prog Urol 2005; 15: 1085\u20131089.","journal-title":"Prog Urol"},{"key":"BFpcan20121_CR68","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S0090-4295(01)01408-X","volume":"58","author":"L Sandfeldt","year":"2001","unstructured":"Sandfeldt L, Bailey DM, Hahn RG . Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 2001; 58: 972\u2013976.","journal-title":"Urology"},{"key":"BFpcan20121_CR69","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0022-5347(05)64287-5","volume":"168","author":"JF Donohue","year":"2002","unstructured":"Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC . Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002; 168: 2024\u20132026.","journal-title":"J Urol"},{"key":"BFpcan20121_CR70","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/00365599309182284","volume":"27","author":"J Ekengren","year":"1993","unstructured":"Ekengren J, Hahn RG . Blood loss during transurethral resection of the prostate as measured with the HemoCue photometer. Scand J Urol Nephrol 1993; 27: 501\u2013507.","journal-title":"Scand J Urol Nephrol"},{"key":"BFpcan20121_CR71","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/00365590510007694","volume":"39","author":"L Lund","year":"2005","unstructured":"Lund L, Ernest-Jensin K, Torring N, Erik Nielsen J . Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: A prospective randomized study. Scan J Urol Neph 2005; 39: 160\u2013162.","journal-title":"Scan J Urol Neph"},{"key":"BFpcan20121_CR72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000082709","volume":"74","author":"G Crea","year":"2005","unstructured":"Crea G, Sanfilippo G, Anastasi G, Magno C, Vizzini C, Inferrera A . Presurgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int 2005; 74: 51\u201353.","journal-title":"Urol Int"},{"key":"BFpcan20121_CR73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/sj.pcan.4500818","volume":"8","author":"\u00d6L \u00d6zdal","year":"2005","unstructured":"\u00d6zdal \u00d6L, Ozden C, Benli K, Gokkaya S, Bulut S, Memis A . Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate Cancer Prostatic Dis 2005; 8: 215\u2013218.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan20121_CR74","first-page":"2000","volume":"684","author":"J Hagerty","year":"1955","unstructured":"Hagerty J, Ginsberg P, Harmon J, Harkaway R . Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 55; 684: 2000.","journal-title":"Urology"},{"key":"BFpcan20121_CR75","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S0022-5347(01)63564-X","volume":"159","author":"MM Collins","year":"1998","unstructured":"Collins MM, Stafford RS, O\u2019Leary MP, Barry MJ . How common is prostatitis? A national survey of physician visits. J Urol 1998; 159: 1224.","journal-title":"J Urol"},{"key":"BFpcan20121_CR76","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jama.282.3.236","volume":"282","author":"JN Krieger","year":"1999","unstructured":"Krieger JN, Nyberg Jr L, Nickel JC . NIH consensus definition and classification of prostatitis. JAMA 1999; 282: 236\u2013237.","journal-title":"JAMA"},{"key":"BFpcan20121_CR77","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/j.ijantimicag.2007.07.028","volume":"31S","author":"J Nickel","year":"2008","unstructured":"Nickel J . Treatment of chronic prostatitis\/chronic pelvic pain syndrome. Int J Antimic Agent 2008; 31S: S112\u2013S116.","journal-title":"Int J Antimic Agent"},{"key":"BFpcan20121_CR78","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1046\/j.1464-410x.2001.02193.x","volume":"87","author":"JC Nickel","year":"2001","unstructured":"Nickel JC, True LD, Kreiger JN, Berger RE, Baog AH, Young ID . Consensus development of a histopathological classification system for chronic prostatic inflammation. Br J Urol Int 2001; 87: 797\u2013805.","journal-title":"Br J Urol Int"},{"key":"BFpcan20121_CR79","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/00365599709070335","volume":"31","author":"M Holm","year":"1996","unstructured":"Holm M, Meyhoff H . Chronic prostatic pain: a new treatment option with finasteride? Scand J Urol Nephrol 1996; 31: 213\u2013215.","journal-title":"Scand J Urol Nephrol"},{"key":"BFpcan20121_CR80","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0090-4295(98)00540-8","volume":"53","author":"M Leskinen","year":"1999","unstructured":"Leskinen M, Lukkarinen O, Marttilla T . Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo controlled, pilot study. Urology 1999; 53: 502\u2013505.","journal-title":"Urology"},{"key":"BFpcan20121_CR81","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/01.ju.0000101487.83730.80","volume":"171","author":"SA Kaplan","year":"2004","unstructured":"Kaplan SA, Volpe MA, Te AE . A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis\/chronic pelvic pain syndrome. J Urol 2004; 171: 284\u2013288.","journal-title":"J Urol"},{"key":"BFpcan20121_CR82","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/j.1464-410X.2003.04766.x","volume":"93","author":"J Nickel","year":"2004","unstructured":"Nickel J, Downey J, Pontari M, Shoskes D, Zietlin S . A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int 2004; 93: 991\u2013995.","journal-title":"BJU Int"},{"key":"BFpcan20121_CR83","first-page":"341","volume-title":"Male Lower Urinary Tract Dysfunction, Evaluation And Management","author":"AJ Shaeffer","year":"2006","unstructured":"Shaeffer AJ, Anderson RU, Krieger JN . The assessment and management of male pelvic pain syndrome, including prostatitis. Male Lower Urinary Tract Dysfunction, Evaluation And Management. Heath Publications: Paris, 2006, 341\u2013385."}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan20121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan20121","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan20121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:25:25Z","timestamp":1648675525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan20121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,14]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["BFpcan20121"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2012.1","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,14]]},"assertion":[{"value":"23 September 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}